RARE PHOTOS: Climb org | Rare Historical Photos

Climb Bio (NASDAQ:CLYM) outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright’s BioConnect Conference, with management emphasizing two biologic drug programs aimed at immune-mediated diseases, including nephrology and hematology indications.

While some investors focus on high-growth opportunities, others look for value — companies that appear priced below their intrinsic worth based on underlying fundamentals. For those investors, spotting potentially undervalued stocks is essential. Here's a look at five technology names showing notable strength that may be flying under the radar.